Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dostarlimab in resectable pMMR/MSS colon cancer
2024-512499-36-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dostarlimab in colon adenocarcinoma and colon cancer, sponsored by UZ Leuven. Primary endpoint: Multi-omic molecular data generation and correlation with pathological response. Planned start Dec 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on 2024-512499-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512499-36-00.